Avid Bioservices (CDMO) Tops Q1 EPS by 2c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. APLD
3. STZ
4. SPY
5. RMR
6. DVN
7. CRGY
8. ZETA
9. ARGX
10. GOOGL

Go back to Avid Bioservices (CDMO) Tops Q1 EPS by 2c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus

Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent Developments

December 9, 2019 4:05 PM EST

-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% --

-- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed --

-- Launched Expanded Process Development Facility and Services --

TUSTIN, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (NASDAQ: CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the... More